Intravitreal Anti-Vegf For The Treatment Of Choroidal Neovascularization Secondary To Ocular Histoplasmosis: A Ten-Year Follow-Up
Posted Date: Apr 20, 2021
- Investigator: Carl Noble
- Specialties:
- Type of Study: Observational/Survey
Purpose: Assess 10-year outcomes of intravitreal anti-VEGF injections (IVI) and verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis syndrome (POHS). Methods: Retrospective, comparative case series of 113 eyes treated with either IVI or combination IVI/PDT for subfoveal or juxtafoveal CNV secondary to POHS from Jan. 2006 to Jan. 2021. Primary outcome, visual acuity (VA). Secondary outcomes, number of annual injections (NAI) and disease-free interval (DFI). Results: Mean follow-up of 13 years. Significant difference in logMAR VA was found in year 1, 0.26 vs 0.56 (P=0.02), for subfoveal CNV in IVI vs IVI/PDT respectively. Significantly fewer NAI for all CNVs in year 2, 1.36 vs 3.07 (P=0.001), and juxtafoveal CNVs in years 9, 1.8 vs 4.6 (P=0.01), and 10, 1.8 vs 4.1 (P=0.04), for IVI/PDT vs IVI respectively. DFI for juxtafoveal CNVs was significantly longer in year 9, 57.94 vs 29.94 mos (P=0.04), and year 10, 58.28 vs 21.78 mos (P=0.01), for IVI/PDT vs IVI respectively. Conclusion: Eyes treated with combination IVI/PDT demonstrated worse VA in year 2, with longer DFI and fewer NAI compared to IVI.
Criteria:
Choroidal Neovascularization Secondary To Ocular Histoplasmosis
Keywords:
Histoplasmosis, Neovascularization, Injection
For More Information:
Carl Noble
419-989-0728
cnoble113@gmail.com